ABSTRACT--Objectives. To assess the comparability of the Tandem-R and IMx serum prostate-specific antigen (PSA) assays across levels of the ratio of free-to-total serum PSA found in a community-based population of healthy men.
Prostate-specific antigen (PSA) is a 33-kDa serine protease produced by the epithelium of the prostate gland. 1 Serum levels of PSA have been noted to be elevated m men with an enlarged prost~ men harboring prostate cancer. 2,5 In in larged prostates, elevated PSA levels ha sumed to be due to increased epithelial tissue destruction and concomitant lea into the systemic circulation are also contribute to elevated levels of PSA il cancer. 6 The measurement of serum ¢idespread, since serum PSA luable in monitoring the fencer to therapy. 7ql Serum PSA also been used for case finding J some investigators have even PSA for screening for prostatic v, however, is not universally of PSA concentration in the ghtforward as for many other :ipheral circulation, PSA exists ms: as a free, noncomplexed to alpha-1 antichymotrypsin. iested that PSA may exist in a [pha-2 macroglobulin. 21,22 The d PSA complexed to alpha-1 e both measurable by various earch-based assays. The PSA la-2 macroglobulin is not these assays. 2>25 Some of the ,le assays have reported differe different forms of PSA in the n, which has caused some inst that the two most widely .-R and IMx) may not be com-.llar, it has been suggested that the two assays vary greatly disparate relative concentra-:ause the signal from free PSA mt of PSA level with the IMx d report relatively higher val-"_Is as the ratio of free to corn-;. The few data available to asof the potential bias in total :e limited. Some have been detples of patients 26 or based on erformed at PSA concentrations :er than physiologic levels. 2r )resent the results of multiple itions on samples from a cornof men free of prostate cancer. :s were used to determine PSA em-R and IMx assays, and the al PSA (free and complexed) ement of free PSA were deter--~sed immunofluorometric asdeterminations were used to ;,ht into the comparability of Vlx assays, especially with reee to complexed PSA.
L AND METHODS
of the design and implemenlave been described in detail elsewhere. 3,2s-3° The resources of the Rochester Epidemiology Project ~1 were used to identify an age--and residence-stratified random sample of 5135 men aged 40 to 79 years from the Olmsted County, Minnesota population. Men with a documented history of prostate cancer, prostatectomy, or specified conditions (other than benign prostatic hyperptasia [BPH] ) that would interfere with voiding function were excluded from the study (n = 1261). The remaining 3874 (75%) were invited to participate in a prospective cohort study of the natural history of prostatism. Of those identified, 2115 (55%) completed a previously validated questionnaire that assessed urologic and general health. From these men, a random sample of 537 (25%) was invited to the Mayo Clinic for a detailed clinical examination that included obtaining a serum specimen for PSA determination, digital rectal examination, and ultrasonographic examination of the prostate. All 3 diagnostic tests were completed by 475 men (88%). The results prompted 52 men (11%) to undergo an ultrasound-guided biopsy of the prostate, and prostate cancer was found in 4 (8%) of these men. These 4 were excluded from subsequent analyses.
PSA DETERMINATION5
Prior to the clinical examination, study subjects were phlebotomized at a central clinic facility in the morning hours in a nonfasting state. Approximately 15 mL of venous blood were obtained from each subject and divided into 4 aliquots of 3 to 4 mL each. Each aliquot was labeled and logged, and all but 1 placed in frozen storage at -70°C. The unfrozen aliquot was processed immediately in a central laboratory to determine the serum PSA concentration with the Tandem-R PSA assay (Hybritech Inc., San Diego, CA). The results of this determination have been published previously 3
In September 1993, I aliquot of serum was withdrawn from frozen storage for 395 (84%) of the 471 men to determine serum PSA levels with several assays. The frozen samples were transported on dry ice to Turku, Finland, where samples were thawed. There the total and free serum PSA concentrations were determined by research-based immunofluorometric assays. 21,32-34 Total serum PSA concentrations were determined with a monocional-monoclonal assay similar to the previously described assay. 21 The H117 anti-PSA monoclonal antibody was used as the capture antibody and europium-labeled 2H50 anti-PSA as the detection antibody. The Hl17 and H50 antibodies detect different epitopes available on the noncomplexed PSA molecule as well as PSA complexed to serine 994 / VOLUME 44, NUMBE*< 4 protease inhibitors such as alpha-1 antichymotrypsin. This assay provides an equimolar detection of free, noncomplexed PSA and PSA complexed to alpha-1 antichymotrypsin. The concentration of free PSA was selectively determined with a monoclonal-monoclonal assay similar to the previously described assay, 21 except that H1 17 anti-PSA monoclonal antibody was used as the capture antibody and 5A10 as the detection antibody. The 5A10 antibody is specific to the free, noncomplexed form of PSA. 21
The remaining serum was refrozen and transported on dry ice to Eastern Virginia Medical School, where the serum PSA concentration was determined using both the Tandem-R and IMx (Abbott Laboratories, North Chicago, IL) PSA assays. 35 The Tandem-R assay is a dual monoclonal immunoradiometric assay. The IMx PSA assay, however, is a polyclonal-monoclonat microparticle capture enzyme immunoassay formatted for the IMx system. Serum PSA determinations were made according to manufacturer's instructions with standard reagents and methods of quality control. For this report, analyses are restricted to the more recent determinations from frozen specimens.
STATISTICAL. ANALYSES
The distributions of serum PSA determinations by Tandem-R, IMx, and the ratio of free-to-total PSA by immunofluorometric analysis were described in terms of the median and 25th and 75th percentile. Systematic differences between the Tandem-R and IMx assay were tested with the sign rank test. Graphic techniqnes were used to examine the relationship between the difference between the two assays and PSA level and ratio of free-tototal PSA and total PSA determined by the IFMA) 6,3r
The association was quantified with the Spearman rank correlation coefficient. Linear least-squares regression analyses were performed within strata defined by the 10th, 2_ ~ percentiles of the distribl total PSA. Regression mc the IMx result as the de dem-R result as the inde 1 of the slope and intercep els were used to describe between the two assays. assays were in complete slope from the regressio the intercept would be, confidence interval abot excludes the null hypotl intercept), the coeffieiel from the null value (p <C formed using SAS Stati: tute, Cary, NC).
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The distributions of s are presented in Table I . sample of men, the d whether determined by strikingly similar. The, assays was 0.13 ng/mL, s the IMx assay determin; than Tandem-R (p <0.1 the IMx and Tandem-R results with the IFMA ( ficity for the IMx, Tan were 93.8%, 93.8%, ant the cntpoint set at 4.0 ficity decreased with in( specific reference ranges ficities were 95.6%, 95. c free-to-total PSA rangec median of 0.29. If the c free-to-total ratio was se pie would be labeled no: labeled abnormal. • . .. :% r .
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".:::-:'.'~7-. ". FIGURE 2 Scatterplot of difference in determination of serum PSA concentration by IMx and Tandern-R assay (IMx minus Tandem-R) by averaged deterrnina-
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:o serum PSA determinaterminations by IMx were slightly higher than by is plotted against the avas in Figure 2 . Although above 0, there did not upward or downward eels (r s = 0.03, p = 0.61). ".Is, whether determined ed to be higher in samee-to-total PSA (Fig. 3 ) of the ratio (rs = -0.49 th p <0.001). When the eterminations was plot-:e-to-total PSA (Fig. 4) , dication of a slight inof the free-to-total ratio, Tere slightly lower than of free-to-total PSA, de- The stratified regression analyses provide further insight into the relationship between Tandern-R and IMx assays at different levels of free-to-total PSA ratios (Table II) . In the groups with cutpoints determined by the 10th, 25th, 50th, 75th, and 90th percentiles, the estimates of slope in the regression of IMx determination on Tandem-R determination were significantly different than 1.0 in only the upper and lower 10th percentiles. Furthermore, the estimates of intercept were significantly differ--ent than 0 in only the higher levels of free-to-total ratio• This suggests that for the majority of men the difference between lMx and Tandem-R determinations is fairly constant, with .only a slight upward shift in determination by IMx assay. long-term comparisons of PSA determinations on frozen serum samples suggest that PSA is stable when handled properly, as in this study# ° In summary, these data provide important reassurances about the comparability of the Tandem-R and IMx assays for serum PSA levels. For most men, they provide nearly identical levels. There are situations, however, in which they are not quite so close, especially at extremes of the ratios of free-tototal serum PSA. This must be kept in mind when assessing men thought to have BPH in whom the free-to-total ratio may be elevatedJ s In these men, the IMx assay may provide slightly higher determinations than the Tandem-R, which might yield slightly more false-positive results for prostate cancer. In men with prostate cancer (in whom the ratio may be relatively lower), the IMx may provide determinations slightly lower than the Tandem-R, potentially resulting in slightly more false-negative results for prostate cancer. Most important, however, the small differences should be accounted for in sequential determinations made in a given patient with the two assays. At this time, however, it is not apparent which of these assays may provide the most useful, predictive information in the management of prostate disease. Further study will be required to provide a better understanding of the role that determination of serum levels of PSA, measured in the free, complexed, or total form can play.
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